封面
市场调查报告书
商品编码
1728365

治疗性 BCG 疫苗市场 - 全球行业规模、份额、趋势、机会和预测,按类型(免疫 BCG、治疗性 BCG)、按人口统计(成人、儿科)、按最终用户(诊所、医院)、按地区和竞争细分,2020-2030F

Therapeutic BCG Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type (Immune BCG, Therapy BCG), by Demographics (Adults, Pediatrics), by End User (Clinics, Hospitals), By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球治疗性 BCG 疫苗市值为 6,029 万美元,预计到 2030 年将达到 7,568 万美元,预测期内复合年增长率为 3.86%。 BCG疫苗(卡介苗)仍是唯一获准用于预防结核病(TB)的疫苗。它通常在结核病流行国家出生时注射,并在结核病低发病率地区对高风险婴儿进行注射,有助于预防结核病,结核病主要影响肺部,但可能扩散到其他器官。由于其有效性,卡介苗也被纳入国家免疫接种计划。除了结核病之外,随着持续研究的推进,卡介苗的治疗应用范围正在扩大,涵盖膀胱癌、自体免疫疾病和各种癌症等疾病。这种更广泛的治疗范围,加上其既定的安全性和可近性,继续支持市场稳定成长。

市场概览
预测期 2026-2030
2024年市场规模 6029万美元
2030年市场规模 7568万美元
2025-2030 年复合年增长率 3.86%
成长最快的领域 免疫BCG片段
最大的市场 北美洲

关键市场驱动因素

生物技术进步

主要市场挑战

疫苗短缺

主要市场趋势

结核病(TB)的治疗与预防

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球治疗性卡介苗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型(免疫 BCG、治疗 BCG)
    • 按最终用户(诊所、医院)
    • 按国家/地区
    • 按公司分类(2024)
  • 市场地图

第六章:亚太地区治疗性卡介苗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第七章:欧洲治疗性卡介苗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第八章:北美治疗性卡介苗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第九章:南美洲治疗性卡介苗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章:中东和非洲治疗性卡介苗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章:全球治疗性 BCG 疫苗市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • Merck & Co., Inc.
  • Sanofi Pasteur Inc.
  • Japan BCG Laboratory
  • China National Biotec Group
  • Serum Institute of India Pvt. Ltd,
  • InterVax Ltd
  • GreenSignal Bio Pharma Limited
  • Statens Serum Institute
  • PowderJect Pharmaceuticals Ltd.
  • Biomed Lublin

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 16984

The Global Therapeutic BCG Vaccine Market was valued at USD 60.29 Million in 2024 and is projected to reach USD 75.68 Million by 2030, growing at a CAGR of 3.86% during the forecast period. The BCG vaccine (Bacillus Calmette-Guerin) remains the only approved vaccine for tuberculosis (TB) prevention. Typically administered at birth in TB-endemic countries, and to high-risk infants in low-incidence regions, it helps prevent TB, which primarily affects the lungs but may spread to other organs. BCG is also incorporated in national immunization schedules due to its effectiveness. Beyond TB, therapeutic applications of the BCG vaccine are expanding to include diseases like bladder cancer, autoimmune disorders, and various cancers, driven by ongoing research. This broader therapeutic scope, along with its established safety and accessibility, continues to support steady growth in the market.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 60.29 Million
Market Size 2030USD 75.68 Million
CAGR 2025-20303.86%
Fastest Growing SegmentImmune BCG Segment
Largest MarketNorth America

Key Market Drivers

Biotechnology Advancements

Biotechnology advancements involve innovations in utilizing biological systems and organisms to develop new technologies and products that improve human health and other sectors. In healthcare, progress in genetic engineering-such as the use of CRISPR-Cas9-has enabled precise gene editing, leading to breakthroughs in vaccine development, including therapeutic BCG vaccines. Additionally, the rise of biopharmaceuticals such as monoclonal antibodies and gene therapies is reshaping treatment approaches. Personalized medicine, driven by human genome sequencing and advanced genomics, is also emerging, enabling more targeted and effective treatments. Stem cell research continues to offer promise in regenerative medicine and organ repair. Synthetic biology further supports the creation of engineered organisms for practical uses in health, industry, and the environment. Together, these advancements enhance the development and application of therapeutic BCG vaccines across various disease areas.

Key Market Challenges

Vaccine Shortages

Producing BCG vaccines is a sensitive and intricate process, requiring controlled conditions to culture live bacteria. Any disruption-such as contamination or quality issues-can significantly hamper production. The global supply is dependent on a limited number of manufacturers, making the market susceptible to disruptions if one producer faces setbacks. Strict regulatory and quality control standards, although necessary, can delay production or cause batch rejections. Variability in demand due to disease trends or clinical trial requirements adds to the difficulty in maintaining consistent supply. Furthermore, imbalances in regional distribution and unexpected spikes in demand, such as during outbreaks or new therapeutic applications, can quickly deplete stockpiles and exacerbate shortages.

Key Market Trends

Tuberculosis (TB) Treatment and Prevention

The BCG vaccine has long been used to prevent tuberculosis, especially in areas with a high disease burden, by reducing the risk of infection and severe forms of TB in children. Beyond prevention, BCG is used in immunotherapy to treat non-muscle-invasive bladder cancer (NMIBC), where it activates the immune system to target cancer cells. Research is expanding into new therapeutic areas, exploring its potential in autoimmune diseases, infectious diseases, and other types of cancer. The emergence of drug-resistant TB strains, such as MDR-TB and XDR-TB, has further heightened the relevance of BCG vaccines, prompting investigations into their use as complementary treatments in drug-resistant TB management.

Key Market Players

  • Merck & Co., Inc.
  • Sanofi Pasteur Inc.
  • Japan BCG Laboratory
  • China National Biotec Group
  • Serum Institute of India Pvt. Ltd,
  • InterVax Ltd
  • GreenSignal Bio Pharma Limited
  • Statens Serum Institute
  • PowderJect Pharmaceuticals
  • Biomed Lublin

Report Scope:

In this report, the Global Therapeutic BCG Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic BCG Vaccine Market, By Type:

  • Immune BCG
  • Therapy BCG

Therapeutic BCG Vaccine Market, By End User:

  • Clinics
  • Hospitals

Therapeutic BCG Vaccine Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic BCG Vaccine Market.

Available Customizations:

Global Therapeutic BCG Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic BCG Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immune BCG, Therapy BCG)
    • 5.2.2. By End User (Clinics, Hospitals)
    • 5.2.3. By Country
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Therapeutic BCG Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Therapeutic BCG Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. India Therapeutic BCG Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Australia Therapeutic BCG Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User
    • 6.3.4. Japan Therapeutic BCG Vaccine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By End User
    • 6.3.5. South Korea Therapeutic BCG Vaccine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By End User

7. Europe Therapeutic BCG Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Therapeutic BCG Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany Therapeutic BCG Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Spain Therapeutic BCG Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Therapeutic BCG Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. United Kingdom Therapeutic BCG Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. North America Therapeutic BCG Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Therapeutic BCG Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Mexico Therapeutic BCG Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Canada Therapeutic BCG Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User

9. South America Therapeutic BCG Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutic BCG Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Therapeutic BCG Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Therapeutic BCG Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Therapeutic BCG Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutic BCG Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Therapeutic BCG Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Therapeutic BCG Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Therapeutic BCG Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Merck & Co., Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Sanofi Pasteur Inc.
  • 16.3. Japan BCG Laboratory
  • 16.4. China National Biotec Group
  • 16.5. Serum Institute of India Pvt. Ltd,
  • 16.6. InterVax Ltd
  • 16.7. GreenSignal Bio Pharma Limited
  • 16.8. Statens Serum Institute
  • 16.9. PowderJect Pharmaceuticals Ltd.
  • 16.10.Biomed Lublin

17. Strategic Recommendations

18. About Us & Disclaimer